Lurbinectedin Injection
92 interactions 305 cited referencesLurbinectedin injection is used to treat small cell lung cancer (SCLC) that has spread to other parts of the body and did not improve during or after treatment with platinum chemotherapy. Lurbinectedin injection is in a class of medications called alkylating agents. It works by slowing or stopping the growth of cancer… Read the full Lurbinectedin Injection drug information page →
Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →
Major
Lurbinectedin Injection Telaprevir Increased lurbinectedin exposure and an increased risk of lurbinectedin-related adverse reactions Details Lurbinectedin Injection Telithromycin Increased lurbinectedin exposure and an increased risk of lurbinectedin-related adverse reactions Details Lurbinectedin Injection Treosulfan Grafapex Increased lurbinectedin exposure and an increased risk of lurbinectedin-related adverse reactions Details Lurbinectedin Injection Troleandomycin Increased lurbinectedin exposure and an increased risk of lurbinectedin-related adverse reactions Details Lurbinectedin Injection Tucatinib Tukysa Increased lurbinectedin exposure and an increased risk of lurbinectedin-related adverse reactions Details Lurbinectedin Injection Verapamil Calan Increased lurbinectedin exposure and an increased risk of lurbinectedin-related adverse reactions Details Lurbinectedin Injection Voriconazole Vfend Increased lurbinectedin exposure and an increased risk of lurbinectedin-related adverse reactions Details Lurbinectedin Injection Voxelotor Oxbryta Increased lurbinectedin exposure and an increased risk of lurbinectedin-related adverse reactions DetailsModerate
Lurbinectedin Injection Artemether Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Lurbinectedin Injection Kratom Increased CYP3A substrate exposure Details Lurbinectedin Injection Mavacamten Camzyos Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Lurbinectedin Injection Rilzabrutinib Wayrilz Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions DetailsNo interactions on this page match that filter — try the next page or clear the filter.
Check another drug
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist